Medimmune Limited

Formatech, Inc.

Arexis Ab

Javeri, Indu

Benjamin S Isaacs

Christian B Allan

Erica Shane

Stephen T Chang

Cynthia N Oliver

Kaliappanadar Nellaiappan

Indu Isaacs

John G Augustine

Heather E Hughes

Suzanne P McKenzie

Jennifer L Ray

Joshua N Isaacs

Katrina M Brown

Rachel C Isaacs

Indu J Isaacs Isaacs

The present invention provides liquid formulations of SYNAGIS&#xae; or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS&#xae; or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS&#xae; or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

Stabilized liquid anti-RSV antibody formulations

The present invention provides liquid formulations of SYNAGIS&#xae; or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulation exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS&#xae; or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS&#xae; or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulation are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

The present invention provides liquid formulations of SYNAGIS&#xae; or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS&#xae; or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS&#xae; or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

This invention concerns novel methods of enhancing the solubility of a compound. Compositions prepared using such methods are also disclosed. Compositions prepared using the methods have various advantages over conventionally known compositions.

Pharmaceutical compositions of hydrophobic compounds

Methods of enhancing solubility of agents

Methods of enhancing solubility of compounds

The invention relates to a working pipettor station comprising an exterior frame and an interior support. The pipettor station is used in conjunction with a pipettor which is in use (i.e., with a pipettor tip attached) and requires temporary and secured positioning or storage. Optionally, an apron can be an additional component of the working pipettor station.

Working pipettor station

Growing community of inventors

Andover, MA, United States of America

Benjamin S Isaacs